Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

FluoroPharma Medical, Inc. (FPMI) Board Of Directors Provide Invaluable Experience And Direction

It's hard to imagine a successful company without a board of directors that is insightful, responsible, and comfortable with any technologies involved in the company's products or operations. A board is, after all, generally responsible for formulating and establishing broad company objectives, thereby setting the general direction of the company.

In the case of FluoroPharma Medical, a Boston-based developer of proprietary medical diagnostic imaging products for use with positron emission tomography (PET) scanning systems, the emphasis is on the technology side of the equation, reflected strongly in the company's small but critical board of directors made up of the company's key officers.

• David Elmaleh, PhD (Chairman, Director, Chief Scientific Advisor) is the Scientific Founder of FluoroPharma, an Associate Professor of Harvard Medical School, and Director of Contrast Media Chemistry at the Massachusetts General Hospital. Dr. Elmaleh is the inventor of three drugs currently in use or in late stage clinical trials, and has done extensive research on imaging compounds. He is a co-author of over 120 publications, as well as an inventor of more than 40 issued and pending patents. He is also the Scientific Founder of Biostream, now Molecular Insight Pharmaceuticals, and other start-ups.

• Thiis Spoor, MBA (Director, CEO, and President) was previously the CFO for Sunstone BioSciences. He holds a degree in Nuclear Pharmacy, and has an MBA from Columbia with concentrations in Finance and Accounting. He's been a guest lecturer at Columbia Business School, Kings College in London, and the University of Newcastle in Australia. He has extensive experience in helping pharmaceutical and medical device companies evaluate their global revenue potential, given the complex interplay of regulatory approvals and other factors. He has also performed equity research analysis for JP Morgan and Credit Suisse, covering the Biotechnology and Medical Device industries.

• Bovan Goumnerov, MD (COO & VP Clinical Trials) has held executive level positions in healthcare and biomedical research. He was President of VasoStent, Inc., and Managing Director of CardioVas, Inc., both medical device start-ups in cardiac imaging and therapy. He's done research in surgery and molecular biology at the Massachusetts General Hospital and The Shriners Burn Hospital for Children in Boston, where he held academic appointments with Harvard Medical School. He is co-author of many scientific publications.

For more information, see the company website at www.FluoroPharma.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html